Pfizer Ltd.

PFIZER

₹5062.2

-0.57% (-29.0)

Market Cap

₹23,187 Cr.

P/E

27.16

Key Ratios

Edit Ratio's

Market cap

23,187 Cr

27.16

Prom Holding

63.92 %

ROE (%)

18.20

ROCE (%)

19.94

Div Yield (%)

3.25

Sales

2,482 Cr

OPM (%)

36.08 %

Debt to Equity

0.00

Edit Ratio's

About

Pfizer Limited is a pharmaceutical company involved in the manufacturing, marketing, trading, … Read more

Low

3701

52W Range

High

5993

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Other Income

Other income component is making ratios of the company look optically better
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Capex vs ROCE

Roce of the company has decreased even without significant capex
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

20 %

(as of Mar 24)

Source/Historic

Antacid (Gelucil) - Market Share

0 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

2.98 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.14 %

(as of May 19)

Historic

Anti-Malarial - Market Share

67 %

(as of Mar 24)

Source/Historic

Anticholinergics ( Pacitane) - Market Share

2.34 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

75.10 %

(as of Mar 21)

Source/Historic

Becosules - Market Share

6.08 %

(as of Nov 21)

Historic

Blood Related - Market Share

1.88 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

39 %

(as of Mar 19)

Source/Historic

Cefoperazone Sulbactam - Market Share

15 %

(as of Mar 24)

Source/Historic

Corex Dx - Market Share

0.05 %

(as of Nov 21)

Historic

Dermatology - Market Share

29.70 %

(as of Mar 22)

Source/Historic

Eliquis - Market Share

30 %

(as of Mar 19)

Source/Historic

Enbrel - Market Share

11.34 %

(as of Nov 21)

Historic

Endocrinology - Market Share

7.50 %

(as of Mar 19)

Source/Historic

Folvite - Market Share

1.82 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

4.45 %

(as of Nov 21)

Historic

Gynecology - Market Share

44 %

(as of Mar 24)

Source/Historic

Hypertension (Minipress) - Market Share

1 %

(as of Mar 19)

Source/Historic

Lyrica - Market Share

6.70 %

(as of Mar 23)

Source/Historic

Magnex - Market Share

5.50 %

(as of Mar 23)

Source/Historic

Meronem - Market Share

2.72 %

(as of Nov 21)

Historic

Neurological - Market Share

1.15 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

1.78 %

(as of Nov 21)

Historic

Pain - Market Share

1.70 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

1.87 %

(as of Nov 21)

Historic

Respiratory - Market Share

1.96 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.01 %

(as of Nov 21)

Historic

Stomatological - Market Share

2.40 %

(as of Nov 21)

Historic

Urology - Market Share

3.58 %

(as of Jul 22)

Historic

Vaccines - Market Share

2.66 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

Domestic Sales Growth - YoY (%)
Source

Peer Comparison

Brands

Autrin

Becosules

Corex Dx

Gelusil

Ovral L

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Tata Communications Ltd.
Piramal Enterprises Ltd. - (Amalgamated)
Aarti Industries Ltd.
AGI Greenpac Ltd.
Suven Life Sciences Ltd.
Aarti Drugs Ltd.
Vidhi Specialty Food Ingredients Ltd.
Gulshan Polyols Ltd.
Snowman Logistics Ltd.
Take Solutions Ltd.
Empire Industries Ltd.
Hindusthan National Glass & Industries Ltd.

Showing 5 of 12

FAQs on Pfizer Ltd. Business

What does Pfizer do?

Pfizer is engaged in manufacturing, marketing, distribution and trading of pharmaceutical products. The company has its own manufacturing facility. The company also has various independent contract / third party manufacturers based across the country. The company sells its products primarily in India through independent distributors.

Who are the competitors of Pfizer?

Pfizer major competitors are Wockhardt, Astrazeneca Pharma I, Eris Lifesciences, Natco Pharma, Gland Pharma, Alembic Pharma, Jubilant Pharmova.
Market Cap of Pfizer is ₹23,533 Crs.
While the median market cap of its peers are ₹18,860 Crs.

Is Pfizer financially stable compared to its competitors?

Pfizer seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Monopoly Companies

Companies which are dominant in a product, usually having a strong moat.

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release					Jun Sep		Mar Jun Sep	Mar Jun	Jun Dec		Mar Sep	Mar Sep Dec	Mar Jun Dec	Sep
Investor Presentation														Mar Sep	Mar Sep Dec
Conference Call							Jun			Mar	Mar Jun Sep Dec	Dec		Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Pharmaceuticals

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Nutraceuticals- Industry Overview - Value Educator

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Pharma Compliance In-Depth - Amit Rajan

Deep Dive into Pharma Sector - Omkara Capital

How The Pharma Industry Works - PPFAS

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Pfizer Ltd.

Pfizer Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

9 Yes

2 Neutral

6 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Pledge

Retail Holding

Promoter Holding

Depreciation Effect

Other Income

Revenue Recognition

Price & Performance

ROE

Share price

Working Capital

Current vs Historic Valuation

Debt

ROCE Strength

Balance Sheet Strength

Capex vs ROCE

Sales Growth

Margin Stability

Market Share

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Brands

Corporate Actions

Suppliers

FAQs on Pfizer Ltd. Business

What does Pfizer do?

Who are the competitors of Pfizer?

Is Pfizer financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE